Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: a brief review

Alves, Késsia Caroline Souza; Guimarães, Jander Matos; Almeida, Maria Edilene Martins de; Mariúba, Luís André Morais

doi:10.1590/s1678-9946202264023

Cited by 9 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is a group of transport proteins which includes the PfMDR1 protein, and polymorphisms in the ABC transporters have been involved in anti-malarial drug resistance 30 . PfMSP3 is a merozoite surface protein and is a potential vaccine candidate 31 .…”

Section: Discussionmentioning

confidence: 99%

Population dynamics and drug resistance mutations in Plasmodium falciparum on the Bijagós Archipelago, Guinea-Bissau

Moss

Mańko

Vasileva

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Following integrated malaria control interventions, malaria burden on the Bijagós Archipelago has significantly decreased. Understanding the genomic diversity of circulating Plasmodium falciparum malaria parasites can assist infection control, through identifying drug resistance mutations and characterising the complexity of population structure. This study presents the first whole genome sequence data for P. falciparum isolates from the Bijagós Archipelago. Amplified DNA from P. falciparum isolates sourced from dried blood spot samples of 15 asymptomatic malaria cases were sequenced. Using 1.3 million SNPs characterised across 795 African P. falciparum isolates, population structure analyses revealed that isolates from the archipelago cluster with samples from mainland West Africa and appear closely related to mainland populations; without forming a separate phylogenetic cluster. This study characterises SNPs associated with antimalarial drug resistance on the archipelago. We observed fixation of the PfDHFR mutations N51I and S108N, associated with resistance to sulphadoxine-pyrimethamine, and the continued presence of PfCRT K76T, associated with chloroquine resistance. These data have relevance for infection control and drug resistance surveillance; particularly considering expected increases in antimalarial drug use following updated WHO recommendations, and the recent implementation of seasonal malaria chemoprevention and mass drug administration in the region.

show abstract

Section: Discussionmentioning

confidence: 99%

Population dynamics and drug resistance mutations in Plasmodium falciparum on the Bijagós Archipelago, Guinea-Bissau

Moss

Mańko

Vasileva

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Since 1994, it was discovered that MSP3-protective antibodies could be discovered in animals and humans. Later in 2003 and 2009, promising findings were obtained in preclinical and phase I clinical trial of the GMZ2 recombinant vaccine (containing MSP3 and glutamate-rich protein, GLURP), and further studies more emphasized on the potency of this MSP3-based vaccine candidates [ 71 ]. Previously, MSP4 was found to be immunogenic in nature both during natural infection and in laboratory animals, with limited gene polymorphism which simplifies the vaccine formulations [ 72 ].…”

Section: Discussionmentioning

confidence: 99%

Computational Clues of Immunogenic Hotspots in Plasmodium falciparum Erythrocytic Stage Vaccine Candidate Antigens: In Silico Approach

Azimi-Resketi

Heydaryan

Kumar

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Malaria is the most pernicious parasitic infection, and Plasmodium falciparum is the most virulent species with substantial morbidity and mortality worldwide. The present in silico investigation was performed to reveal the biophysical characteristics and immunogenic epitopes of the 14 blood-stage proteins of the P. falciparum using comprehensive immunoinformatics approaches. For this aim, various web servers were employed to predict subcellular localization, antigenicity, allergenicity, solubility, physicochemical properties, posttranslational modification sites (PTMs), the presence of signal peptide, and transmembrane domains. Moreover, structural analysis for secondary and 3D model predictions were performed for all and stable proteins, respectively. Finally, human helper T lymphocyte (HTL) epitopes were predicted using HLA reference set of IEDB server and screened in terms of antigenicity, allergenicity, and IFN-γ induction as well as population coverage. Also, a multiserver B-cell epitope prediction was done with subsequent screening for antigenicity, allergenicity, and solubility. Altogether, these proteins showed appropriate antigenicity, abundant PTMs, and many B-cell and HTL epitopes, which could be directed for future vaccination studies in the context of multiepitope vaccine design.

show abstract

“…The study, using CHMI by intravenously injecting live P. falciparum sporozoites (PfSPZ Challenge) to assess vaccine efficacy, showed that the use of the novel adjuvant CAF01 did not significantly affect vaccine efficacy [132]. Despite being immunogenic, MSP3-based vaccines face significant challenges in achieving improved protective efficacy [133].…”

Section: Msp3 and Gmz2mentioning

confidence: 99%

The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates for Plasmodium falciparum

Takashima,

Otsuki,

Morita

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Extensive control efforts have significantly reduced malaria cases and deaths over the past two decades, but in recent years, coupled with the COVID-19 pandemic, success has stalled. The WHO has urged the implementation of a number of interventions, including vaccines. The modestly effective RTS,S/AS01 pre-erythrocytic vaccine has been recommended by the WHO for use in sub-Saharan Africa against Plasmodium falciparum in children residing in moderate to high malaria transmission regions. A second pre-erythrocytic vaccine, R21/Matrix-M, was also recommended by the WHO on 3 October 2023. However, the paucity and limitations of pre-erythrocytic vaccines highlight the need for asexual blood-stage malaria vaccines that prevent disease caused by blood-stage parasites. Few asexual blood-stage vaccine candidates have reached phase 2 clinical development, and the challenges in terms of their efficacy include antigen polymorphisms and low immunogenicity in humans. This review summarizes the history and progress of asexual blood-stage malaria vaccine development, highlighting the need for novel candidate vaccine antigens/molecules.

show abstract

Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: a brief review

Cited by 9 publications

References 43 publications

Population dynamics and drug resistance mutations in Plasmodium falciparum on the Bijagós Archipelago, Guinea-Bissau

Population dynamics and drug resistance mutations in Plasmodium falciparum on the Bijagós Archipelago, Guinea-Bissau

Computational Clues of Immunogenic Hotspots in Plasmodium falciparum Erythrocytic Stage Vaccine Candidate Antigens: In Silico Approach

The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates for Plasmodium falciparum

Contact Info

Product

Resources

About